Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor-Ivacaftor Effect on Glucose Tolerance in CF
NCT02653027Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of lumacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Fasting Glucose at 6 months. Planned start Jan 2018; status: withdrawn.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02653027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653027.